Dear Editor,Primary malignant tumors of the trachea account for 0.01%-0.4%of all cancer cases[1].Due to their locally aggressive growth,surgical resection including carinal resection and airway reconstruction was most...Dear Editor,Primary malignant tumors of the trachea account for 0.01%-0.4%of all cancer cases[1].Due to their locally aggressive growth,surgical resection including carinal resection and airway reconstruction was most frequently applied for these diseases[2].However,tracheal surgery is technically challenging and is associated with high rates of operative morbidity and mortality.Effective neoadjuvant treatment is expected to reduce the tumor load and lessen the extent of resecting primary tracheal tumors.However,evidence regarding neoadjuvant treatment for tracheal tumors remains relatively scarce and platinumbased doublet chemotherapy remains the standard in this setting.Immune checkpoint inhibitors are a promising approach to neoadjuvant treatment.展开更多
基金This work was supported by the High-level Hospital Construction Project(DFJH201910 to B.Y.J.)Guangdong Provincial People’s Hospital Young Talent Project(GDPPHYTP201902 to W.Z.Z.).
文摘Dear Editor,Primary malignant tumors of the trachea account for 0.01%-0.4%of all cancer cases[1].Due to their locally aggressive growth,surgical resection including carinal resection and airway reconstruction was most frequently applied for these diseases[2].However,tracheal surgery is technically challenging and is associated with high rates of operative morbidity and mortality.Effective neoadjuvant treatment is expected to reduce the tumor load and lessen the extent of resecting primary tracheal tumors.However,evidence regarding neoadjuvant treatment for tracheal tumors remains relatively scarce and platinumbased doublet chemotherapy remains the standard in this setting.Immune checkpoint inhibitors are a promising approach to neoadjuvant treatment.
